Brasil | Otros

Peptide prodrugs for the treatment of CNS disorders: A perspective for new drugs

dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2018-12-11T16:56:14Z
dc.date.available2018-12-11T16:56:14Z
dc.date.created2018-12-11T16:56:14Z
dc.date.issued2014-01-01
dc.identifierCurrent Medicinal Chemistry, v. 21, n. 23, p. 2599-2609, 2014.
dc.identifier1875-533X
dc.identifier0929-8673
dc.identifierhttp://hdl.handle.net/11449/171614
dc.identifier10.2174/0929867321666140217125526
dc.identifier2-s2.0-84903713359
dc.identifier9734333607975413
dc.identifier0000-0003-4141-0455
dc.description.abstractThe treatment of central nervous system (CNS) diseases is a major challenge. The presence of the barrier intended to protect the brain from unwanted molecules also impairs the efficacy of CNS-targeted drugs. The discovery of drug targets for CNS diseases opens a door for the selective treatment of these diseases. However, the physicochemical properties of drugs, including their hydrophilic properties and their peripheral metabolism, as well as the blood-brain barrier, can adversely affect the therapeutic potential of CNS-targeted drugs. Although peptides are often metabolized by enzymes, they are of particular interest for the treatment of CNS diseases or as carriers to deliver drugs to the brain. In this review, we discuss the use of peptides as potential prodrugs for the treatment of CNS diseases. © 2014 Bentham Science Publishers.
dc.languageeng
dc.relationCurrent Medicinal Chemistry
dc.relation1,015
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectBlood-brain barrier
dc.subjectCentral nervous system
dc.subjectHydrophilic
dc.subjectPeptides
dc.subjectPeripheral metabolism
dc.subjectPhysicochemical properties
dc.titlePeptide prodrugs for the treatment of CNS disorders: A perspective for new drugs
dc.typeOtros


Este ítem pertenece a la siguiente institución